TICKERNERD
Menu
APGEAPGEHealthcare · Biotechnology

APGE Stock Forecast: Apogee Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$135
+0.04% on the day

The 15 Wall Street analysts covering Apogee Therapeutics, Inc. hold a median 12-month price target of $135 — +0.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$10.2B
Ticker Nerd rank
36 / 100
Median analyst target
$135
Analysts covering
15
Revenue$0.0
Operating income−$82.8M
Net income−$74.1M
Free cash flow−$55.6M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.2%
1M
+0.4%
YTD
+78.6%
1Y
+252.3%
From 52W high
−0.0%
From 52W low
+270.7%
$36
$135
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

APGE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Apogee Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Volatility
81
Value
79
Quality
52
Growth
41
Revisions
37
Accruals
23
Size
16
Issuance
12

Momentum (100): The shares have been drifting up relative to others.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

APGE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APGE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26APGEHigh $135Median $135Low $133

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
1 Buy14 Hold0 Sell
Low $133Median $135High $135

The green dot is the last close — the median target sits +0.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Aug 2026Truist SecuritiesMaintainsHold$81 → $135
12 Aug 2026BTIGDowngradeNeutral—
24 June 2026GuggenheimDowngradeNeutral—
24 June 2026GuggenheimDowngradeNeutral—
24 June 2026MizuhoDowngradeNeutral$110 → $135
24 June 2026MizuhoDowngradeNeutral—
24 June 2026StifelDowngradeHold$133 → $135
24 June 2026StifelDowngradeHold—
24 June 2026TD CowenDowngradeHold—
24 June 2026TD CowenDowngradeHold—
23 June 2026CitigroupDowngradeNeutral—
23 June 2026CitigroupDowngradeNeutral$125 → $135
23 June 2026Deutsche BankDowngradeHold—
23 June 2026Deutsche BankDowngradeHold$116 → $135
23 June 2026RBC CapitalMaintainsSector Perform—
23 June 2026RBC CapitalMaintainsSector Perform$97 → $135
23 June 2026UBSDowngradeNeutral$100 → $135
23 June 2026UBSDowngradeNeutral—
23 June 2026WedbushDowngradeNeutral—
23 June 2026WedbushDowngradeNeutral$135

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APGE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

APGE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Apogee Therapeutics, Inc. returned +252.3% against +19.6% for the S&P 500, dividends included.

APGE vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Oct 25Jan 26Apr 26Jul 26APGES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APGE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Apogee Therapeutics, Inc. (APGE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−36.0×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
8.5×

Cheaper than 12% of US stocks

EV / EBITDA
−28.6×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−32.5%

Higher than 26% of US stocks

Return on assets
−20.3%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Apogee Therapeutics, Inc. (APGE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Apogee Therapeutics, Inc. has a market value of $10.2B and an enterprise value of $9.2B.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$274.6M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$235.4M, after $830K of capital spending.

  • Shares outstanding: 74.9M.

  • Trailing P/E: −36.0×; forward P/E: −25.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Apogee Therapeutics, Inc. employs 261 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

APGE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APGEApogee Therapeutics, Inc.$10.2B
36
KRYSKrystal Biotech, Inc.$10.3B
79
PRAXPraxis Precision Medicines, Inc.$10.3B
43
KYMRKymera Therapeutics, Inc.$10.0B
74
PTGXProtagonist Therapeutics, Inc.$9.8B
97
SMMTSummit Therapeutics, Inc.$10.5B
19
CYTKCytokinetics, Inc.$10.7B
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Apogee Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APGE news & analysis

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Benzinga · 12 Aug 2026negative

According to the headline, an Apogee Therapeutics analyst is no longer bullish, with the stock listed among the top five downgrades for Wednesday. The excerpt notes that top Wall Street analysts changed their outlook on these names, referencing the full analyst ratings page for all rating changes.

Why it matters — APGE watchers would care because this indicates a Wall Street analyst has turned less positive on the stock following a rating downgrade.

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

GlobeNewsWire · 10 Aug 2026positive

Apogee reported second quarter 2026 financial results and corporate and pipeline updates, including the announcement that AbbVie will acquire the company for $135.11 per share in cash, for a total equity value of approximately $10.9 billion. The company also reported positive 16-week Phase 2 APEX Part B induction dose optimization results supporting the planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year.

Why it matters — APGE watchers would care because the announcement of an acquisition by AbbVie at a set per-share price and promising Phase 2 data advancing a lead pipeline candidate to Phase 3 are significant developments affecting the company's value and outlook.

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE

Business Wire · 30 July 2026negative

Kahn Swick & Foti, LLC is investigating the proposed sale of Apogee Therapeutics to AbbVie, under which shareholders would receive $135.11 per share, to assess whether the consideration and sale process are adequate.

Why it matters — APGE shareholders should be aware that a law firm is scrutinizing the fairness of the sale price and process, which could affect the outcome of the proposed acquisition.

Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research · 28 July 2026neutral

A Zacks Investment Research article compares the year-to-date stock performance of Apogee Therapeutics (APGE) against Iovance Biotherapeutics (IOVA) and the broader medical sector.

Why it matters — This comparison gives APGE investors context on how the stock is tracking relative to a peer and the sector overall year-to-date.

FAQ

Frequently asked questions about APGE stock

What is the APGE stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Apogee Therapeutics, Inc. have a median 12-month price target of $135, with estimates ranging from $133 to $135. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APGE stock a buy right now?

Of the 15 analysts covering Apogee Therapeutics, Inc., 1 rate it a Buy, 14 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apogee Therapeutics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APGE?

As at 22 Aug 2026, Apogee Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will APGE stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +0.1% from the last close, and Ticker Nerd's factor model ranks Apogee Therapeutics, Inc. 36 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APGE stock forecast for 2030?

No analyst covering Apogee Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $133 to $135 over the next 12 months.

How has APGE stock performed over the past year?

Apogee Therapeutics, Inc. returned +252.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Apogee Therapeutics, Inc. do?

Apogee Therapeutics Inc. is a clinical-stage biotechnology company focused on developing biologic medicines for immunological and inflammatory diseases.

What is the latest news on APGE?

The most recent item we track (Benzinga, 12 Aug 2026): "This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday". According to the headline, an Apogee Therapeutics analyst is no longer bullish, with the stock listed among the top five downgrades for Wednesday. The excerpt notes that top Wall Street analysts changed their outlook on these names, referencing the full analyst ratings page for all rating changes.

Company

About Apogee Therapeutics, Inc.

Apogee Therapeutics Inc. is a clinical-stage biotechnology company focused on developing biologic medicines for immunological and inflammatory diseases. Headquartered in Waltham, Massachusetts and founded in 2022, the company concentrates on validated immunology targets and applies advanced antibody engineering to optimize half-life, dosing convenience, and overall therapeutic profile. Its lead program, zumilokibart (formerly APG777), is a monoclonal antibody targeting IL-13, initially developed for atopic dermatitis and also being evaluated in asthma and eosinophilic esophagitis. Beyond this flagship candidate, Apogee is building a diversified pipeline of novel antibodies and combinations, such as APG273, directed at key inflammatory pathways relevant to dermatologic, respiratory, and gastroenterological conditions including asthma, chronic obstructive pulmonary disease, and other type 2 inflammatory disorders. Operating as a single reportable segment centered on research and development, Apogee collaborates with global clinical and manufacturing partners, aiming to bring differentiated biologic options to large, underserved inflammatory and immunology markets.

CEO Dr. Michael Thomas Henderson M.D. · 261 employees · United States · https://www.apogeetherapeutics.com